Why Cogent Biosciences, Inc. (COGT) stock moved
Cogent Biosciences, Inc. (COGT) shares fell 2.0% to $38.30 as of July 21, 2026, a modest decline from the prior close of $39.08. BestStocks flagged the session as a material change for COGT. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for COGT, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
COGT fell 2.0% to $38.30
COGT fell 2.0% in its latest session, moving from $39.08 to $38.30.
What it means for Cogent Biosciences, Inc. investors
For Cogent Biosciences, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Cogent Biosciences, Inc. (COGT) moved +3.00% from $37.94 to $39.08 on 2026-07-17; Cogent Biosciences, Inc. (COGT) moved +2.80% from $37.46 to $38.51 on 2026-07-14. Weighing against that: Negative session, down 2.0%; Cogent Biosciences, Inc. (COGT) moved −3.46% from $39.30 to $37.94 on 2026-07-16. Wall Street's consensus price target sits at $46.75, implying +22.1% upside from $38.30. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 14 days out, the next report is the most likely near-term test of the move.
COGT price reaction
COGT last traded at $38.30, down $0.78 (-2.00%) from the previous close of $39.08. The session traded on 0.5× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $35.84 and $40.51, and it currently sits about 53% of the way up that band.
Bullish and bearish analyst opinions on Cogent Biosciences, Inc. (COGT)
The consensus analyst price target on Cogent Biosciences, Inc. (COGT) is $46.75, 22.1% above the recent $38.30. Over the past 90 days analysts logged 0 upgrades, 2 maintains, and 0 downgrades. Here is how the bullish and bearish cases on COGT line up.
The bullish case
- Wall Street's consensus price target of $46.75 implies +22.1% upside from $38.30.
- The Street's most bullish target is $55.00 (+43.6%).
- Cogent Biosciences, Inc. (COGT) moved +3.00% from $37.94 to $39.08 on 2026-07-17.
The bearish case
- The most bearish analyst target is $35.00 (-8.6%).
- Negative session, down 2.0%.
- Cogent Biosciences, Inc. (COGT) moved −3.46% from $39.30 to $37.94 on 2026-07-16.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for COGT
Frequently asked questions about COGT
Why did Cogent Biosciences, Inc. (COGT) stock move?
COGT fell 2.0% to $38.30. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did COGT stock fall?
COGT lost 2.00% ($0.78) versus the prior close of $39.08, last trading at $38.30 on 0.5× average volume.
When is Cogent Biosciences, Inc.'s next earnings date?
COGT's next earnings report is estimated for 2026-08-04 — about 14 days away.
What is the analyst price target for COGT?
The consensus analyst price target for COGT is $46.75, about 22.1% above the current $38.30. Over the past 90 days, analysts recorded 0 upgrades, 2 maintains, and 0 downgrades.
How BestStocks tracks COGT
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared COGT-specific materiality thresholds, triggering an evidence check. It draws on 8 tracked change events for COGT, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.